Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Stanford, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: No Disease or Condition is Being Directly Studied, The Focus of the Study in Healthy Volunteers
Interventions: Osteopathic manipulation, Sham; Other
Lead sponsor: Lake Erie College of Osteopathic Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Healthy Adult Participants, Age 65 and Older, Age 18 to 40, Immunology
Interventions: Trivalent inactivated influenza vaccine, RabAvert; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Auburn, Maine

Conditions: Central Nervous System Neoplasm
Interventions: trivalent influenza vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Human Influenza
Interventions: Recombinant Influenza Vaccine, Inactivated Influenza Vaccine; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 254,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Oakland, California

Conditions: Influenza
Interventions: Influenza virus vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Influenza A Vaccine: ACAM FLU-A, Saline placebo; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Miami, Florida • Lenexa, Kansas • Tacoma, Washington

Conditions: Influenza
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1073, mRNA-1010, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 14
States / cities: Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more

Conditions: Influenza (Healthy Volunteers)
Interventions: Exposure to Donors with naturally acquired influenza virus infection; Other
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Influenza
Interventions: GSK influenza virus H5N1 vaccine 1557484A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Atlanta, Georgia • Bethesda, Maryland • Silver Spring, Maryland

Conditions: Influenza, Human
Interventions: bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 5 Years to 8 Years
Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 11
States / cities: Los Angeles, California • Boise, Idaho • St Louis, Missouri + 8 more

Conditions: Influenza
Interventions: Fluzone® (intramuscular), FluMist® (intranasal); Biological
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 100 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Immune Response
Interventions: Flulaval, Fluvirin, Fluzone, Fluarix, Afluria; Biological
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions: ALVR106, Placebo; Biological
Lead sponsor: AlloVir; Industry
Eligibility: 17 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more

Conditions: Viral Lung Infection and Acute Respiratory Failure
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: Influenza, Influenza Immunisation
Interventions: AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more

Conditions: Influenza
Interventions: mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only, mRNA-1018 for H7 Only, mRNA-1018 for H5 Only-CG; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Hollywood, Florida • Savannah, Georgia • Lenexa, Kansas + 6 more

Conditions: Hematopoietic Cell Transplantation
Interventions: Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, Trivalent Influenza Vaccine; Biological · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 4
States / cities: Birmingham, Alabama • Chicago, Illinois • Nashville, Tennessee + 1 more

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Stanford, California • Torrance, California • Baltimore, Maryland + 2 more

Conditions: Healthy Adult Volunteers
Interventions: NB-1008, Fluzone IN; Biological
Lead sponsor: NanoBio Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Influenza, Human
Interventions: Flu shot text messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 74,811 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Danville, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
Interventions: VRC-AVIDNA036-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Optimizing Lymphatic Pumping for Influenza Vaccine Responses in Vulnerable Populations

Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in Humans

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults

Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Evaluating Modes of Influenza Transmission 2b Baseline SAR

Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

Immune Responses Induced by Different Licensed Influenza Vaccines

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Flublok or Fluzone With Advax-CpG55.2 or AF03

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally